MXCT vs PSA
MaxCyte Inc (MXCT) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
PSA (PSA) common stock.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
MXCT currently screens at market cap $124.3M. PSA currently screens at market cap $0.
Not investment advice. Open the MXCT and PSA stock pages for the full models.
Not investment advice.